Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Pompe disease (glycogen storage disease type II) is a glycogen storage disease caused by a deficiency of the lysosomal enzyme, acid maltase/acid alpha-1,4 glucosidase (GAA). Deficiency of the enzyme leads primarily to intra-lysosomal glycogen accumulation, primarily in cardiac and skeletal muscles, due to the inability of converting glycogen into glucose. Enzyme replacement therapy (ERT) has been applied to replace the deficient enzyme and to restore the lost function. However, enhancing the enzyme activity to the muscle following ERT is relatively insufficient. In order to enhance GAA activity into the muscle in Pompe disease, efficacy of hyaluronidase (hyase) was examined in the heart, quadriceps, diaphragm, kidney, and brain of mouse model of Pompe disease. Administration of hyase 3000 U/mouse (intravenous) i.v. or i.p. (intraperitoneal) and 10 min later recombinant human GAA (rhGAA) 20 mg/kg i.v. showed more GAA activity in hyase i.p. injected mice compared to those mice injected with hyase via i.v. Injection of low dose of hyase (3000 U/mouse) or high dose of hyase (10,000 U/mouse) i.p. and 20 min or 60 min later 20 mg/kg rhGAA i.v. increased GAA activity into the heart, diaphragm, kidney, and quadriceps compared to hyase untreated mice. These studies suggest that hyase enhances penetration of enzyme into the tissues including muscle during ERT and therefore hyase pretreatment may be important in treating Pompe disease.
Matalon
Reuben
R
Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX 77555-0359, USA. rmatalon@utmb.edu
Surendran
Sankar
S
Campbell
Gerald A
GA
Michals-Matalon
Kimberlee
K
Tyring
Stephen K
SK
Grady
James
J
Cheng
Seng
S
Kaye
Edward
E
D000818:Animals; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy / Q000378:metabolism*; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D009928:Organ Specificity; D014018:Tissue Distribution; D016896:Treatment Outcome; D000520:alpha-Glucosidases / Q000008:administration & dosage*
C509951:GAA protein, human; D000520:alpha-Glucosidases; D006821:Hyaluronoglucosaminidase